2′,5′ oligoadenyIate synthetase activity in peripheral blood mononuclear cells and serum during interferon treatment of chronic non-A, non-B hepatitis
2′,5′ oligoadenyIate synthetase activity in peripheral blood mononuclear cells and serum during interferon treatment of chronic non-A, non-B hepatitis
复制标题
干扰素治疗慢性非甲非乙型肝炎期间外周血单核细胞和血清中2,5寡腺苷酸合成酶活性
DOI：
--
复制
发表时间：
1991
期刊：
影响因子：
--
通讯作者：
Y. Sokawa
中科院分区：
文献类型：
--
作者：
T. Okuno;M. Shindo;K. Arai;M. Matsumoto;M. Takeda;K. Kashima;Y. Sokawa
本文对23例慢性非甲非乙型肝炎患者在干扰素治疗期间进行了外周血单个核细胞及血清2′-5′寡腺苷酸合成酶（2- 5AS）活性测定，其中16例患者血清中有抗-HCV抗体。患者每天接受100万、300万或600万单位的人干扰素-α或-β，持续4至6周。治疗前2-5 AS活性与正常对照组及慢性B型肝炎患者比较无显著性差异。然而，在治疗期间，2-5 AS活性从初始水平增加2- 41倍。23例患者中有15例（65.2%）在治疗开始后迅速恢复正常，但其余8例（34.8%）仍升高。15例患者中有6例（40%）在治疗结束后6至30个月内ALT水平始终正常。2-5 AS活性变化模式在应答者和非应答者之间无显著差异，但在治疗期间ALT水平未恢复正常的患者中，治疗前外周血单个核细胞中的活性水平显著较高（P< 0.001）。ALT正常组抗-HCV阳性率明显高于ALT正常组（P< 0.05）。因此，这些结果表明，治疗前2-5 AS活性和抗-HCV检测可能是预测干扰素治疗反应的有用参数。
SummaryThe 2′-5′ oligoadenyIate synthetase (2-5 AS) activity of peripheral blood mononuclear cells and serum was measured in 23 patients with chronic non-A, non-B hepatitis during interferon therapy, 16 of whom were found to have antibody to hepatitis C virus (anti-HCV). Patients received a daily dose of either 1 million, 3 million or 6 million units of human interferon-αor-β for 4 to 6 weeks. Before treatment, the 2-5 AS activity was not significantly different from that in normal control subjects or patients with chronic hepatitis B. However, during treatment the 2-5 AS activity increased 2- to 41-fold from the initial level. AIanine aminotransferase (ALT) levels normalized promptly after the start of treatment in 15 (65.2%) of the 23 patients, but remained elevated in the remaining 8 (34.8%). Six (40%) of the 15 patients showed consistently normal ALT levels for 6 to 30 months after the end of treatment. There was no significant difference between the responders and non-responders in the pattern of change of 2-5 AS activity, but pretreatment activity levels in peripheral blood mononuclear cells were significantly higher (P< 0.001) in the patients whose ALT levels did not normalize during treatment. The frequency of patients with a positive anti-HCV was significantly higher (P< 0.05) in the group in which ALT levels normalized. Therefore, these findings suggest that the pretreatment 2-5 AS activity and the detection of anti-HCV may be useful parameters for predicting the response to interferon therapy.
非甲非乙型输血后肝炎——十年后。
影响因子：
29.4
作者：
Koretz,RL;Stone,O;Mousa,M;Gitnick,GL
通讯作者：
Gitnick,GL